Pathologic response and safety of preoperative treatment regimens in gastric cancer undergoing D2 gastrectomy: a real-world cohort study

Key Points

• Pathological response improved with preoperative immunotherapy, particularly the triple combination, without added risk.
• Key metric: preoperative treatment regimens led to enhanced responses, particularly in patients with favorable PD-L1 expression.
• Observational analysis of real-world data highlighted tumor biology, such as Lauren subtype's role, in influencing treatment outcomes.
• The findings suggest the importance of biomarker-guided strategies to tailor preoperative treatments, optimizing patient outcomes.

Abstract